Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine clesrovimab-cfor (Enflonsia) for preventing respiratory syncytial virus (RSV) in newborns and infants entering their first RSV season.

There are now two monoclonal antibody shots to help protect infants against RSV. The other, called nirsevimab-alip (Beyfortus), was approved in July 2023.
In a statement, Merck said the vaccine is given as a 105 mg dose and is designed to provide direct, rapid protection through 5 months, the length of a typical RSV season. It added that Enflonsia is the only RSV preventive that is administered to infants at the same dose, regardless of weight.
Octavio Ramilo, MD, chair of the Department of Infectious Diseases at St. Jude Children’s Research Hospital and investigator for two clinical trials involving the vaccine, said RSV is the leading cause of infant hospitalization and can lead to serious respiratory conditions including bronchiolitis and pneumonia. “Enflonsia combines dosing convenience with strong clinical data showing significant reductions in RSV disease incidence and hospitalizations, making it a promising new intervention to help protect infants from RSV,” Ramilo said.
The approval was based on results from a phase 2b/3 clinical trial that evaluated a single dose given to preterm and full-term infants. The trial met primary and secondary endpoints, reducing RSV-related medically attended lower respiratory infections by 60.5% when compared to placebo over 5 months. Enflonsia also reduced RSV hospitalizations through 5 months by 84.3%, showing increased efficacy with increasing disease severity.
The company said FDA’s approval was also supported by a phase 3 trial that evaluated safety and efficacy when compared to palivizumab, an older monthly monoclonal antibody injection available for high-risk infants, in babies at increased risk for severe disease.
ACIP to discuss recommendation later this month
Merck said the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices is slated to discuss a recommendation for Enflonsia at its meeting later this month and that it anticipated that ordering will begin in July in time for deliveries to begin before the start of the 2025-2026 RSV season.